Commentary: The use of antithyroid drugs in pregnancy and lactation

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 6, 2001, Pages 2354-2359

  Mandel, Susan J ^a,c   Cooper, David S ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c 778 CRB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; PROPYLTHIOURACIL; THIAMAZOLE; THIONAMIDE; THYROID HORMONE; THYROXINE;

CONGENITAL MALFORMATION; FEMALE; FETOMATERNAL TRANSFUSION; FETUS DISEASE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFANT; LACTATION; MAXIMUM TOLERATED DOSE; MOTHER FETUS RELATIONSHIP; NOTE; PREGNANCY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; METABOLISM; PREGNANCY COMPLICATION; REVIEW;

ANTITHYROID AGENTS; FEMALE; HUMANS; HYPERTHYROIDISM; LACTATION; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 0034974976     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.6.2354     Document Type: Note

References (58)

1. Thyroid function and hyperfunction during gestation
2. Thyroid disease in pregnancy: A clinical review
3. Clinical review 80: Management of hyperthyroidism and hypothyroidism in the pregnant woman
4. Hyperthyroidism in pregnancy
5. Hyperthyroidism in pregnancy
6. Hyperthyroidism in pregnancy: Diagnosis and treatment
7. Thyrotoxicosis complicating pregnancy
8. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism
9. Risk factors for developmental disorders in infants born to women with Graves disease
10. Maternal hemodynamics in pregnancies complicated by hyperthyroidism
11. Maternal hyperthyroidism and congenital malformation in the offspring
12. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy
13. Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status
14. Accuracy of free thyroxine measurements across natural ranges of thyroxine binding to serum proteins
15. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism
16. The placental transfer of propylthiouracil, methimazole, and carbimazole
17. Methimazole and propylthiouracil equally cross the perfused human term placental lobule
18. Pharmacology of propylthiouracil (PTU) in pregnant hyperthyroid women: Correlation of maternal PTU concentrations with cord serum thyroid function tests
19. Origin of scalp vertex aplasia cutis
20. Methimazole, carbimazole, and congenital skin defects
21. Maternal methimazole and congenital defects in children
22. Treatment of hyperthyroidism in pregnancy with propylthiouracil and methimazole
23. The association of aplasia cutis congenita with therapy of maternal thyroid disease
24. Elevated α-fetoprotein in pregnancy complicated by aplasia cutis after exposure to methimazole
25. Aplasia cutis after exposure to carbimazole in utero
26. Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis
27. Aplasia cutis congenita after exposure to methimazole: A causal relationship?
28. Aplasia cutis as a teratogenic effect of methimazole
29. Methimazole in animal feed and congenital aplasia cutis
30. Methimazole embryopathy: Delineation of the phenotype
31. Severe malformations in infant born to hyperthyroid woman on methimazole
32. Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance
33. Propylthiouracil disposition in pregnant and post-partum women
34. Serum propylthiouracil concentration in patients with Graves' disease with various clinical course
35. The pharmacokinetics of methimazole in pregnant patients after oral administration of carbimazole
36. Diagnosis and management of Graves' disease in pregnancy
37. Fetal hypothyroidism complicating medical treatment of thyrotoxicosis in pregnancy
38. Resolution of fetal goiter after discontinuation of propylthiouracil in a pregnant woman with Graves' hyperthyroidism
39. Rapid resolution of fetal goiter associated with maternal Grave's (sic) disease: A case report
40. Neonatal thyroid function after propylthiouracil therapy for maternal Graves' disease
41. Graves' disease in pregnancy: TSH receptor binding inhibiting immunoglobulins and maternal and neonatal thyroid function
42. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child
43. Antithyroid drug treatment of Graves' disease in pregnancy: Long-term effects on somatic growth, intellectual development and thyroid function of the offspring
44. Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero
45. 4
46. Relationship between silent thyroiditis and recurrent Graves' disease in the postpartum period
47. Thiouracil. Its absorption, distribution, and excretion
48. Propylthiouracil in human milk
49. Excretion of carbimazole and propylthiouracil in breast milk
50. Antithyriod drugs in milk
51. Excretion of methimazole in human milk
52. Methimazole pharmacology in man: Studies using a newly developed radioimmunoassay for methimazole
53. Thyroid function and intellectual development of infants nursed by mothers taking methimazole
54. The binding of thioureylene compounds to human serum albumin
55. Antithyroid treatment of maternal hyperthyroidism during lactation
56. Recovery from fetal hypothyroidism: Evidence for the safety of breast feeding while taking propylthiouracil
57. Effect of methimazole treatment of maternal thyrotoxicosis on thyroid function in breast feeding infants
58. Thyroid function in wholly breast feeding infants whose mothers take high doses of propylthiouracil